Skip to content

To test the safety of test product by primary irritation patch test on Sensitive Skin

Evaluation of Dermatological Safety of Test Product by 24 Hours Patch Test under Complete Occlusion on Adult Healthy Human Subjects with Sensitive Skin.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/053322
Enrollment
24
Registered
2023-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Gulabari Rose water with Aloe vera : Duration: Once for the period of 9 days Route of Administration: Skin Dosage: Quantity Sufficient Intervention2: Gulabari Organic Rose water: Dura

Sponsors

Dabur India Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age: 18-65 years (both inclusive) at the time of consent. 2.Sex: Males and non-pregnant/non-lactating females (preferably equal numbers of males and females) 3.Subject with normal Fitzpatrick skin type III to V. 4.Subjects scoring greater than 30 for Section 2- Sensitive v/s Resistant skin in modified Dr. Baumann’s skin type questionnaire. 5.Females of childbearing potential must have a negative urine pregnancy test performed on Day 01 prior to patch application. 6.Subject will undergo ‘lactic acid stinging test’ at screening and subject with positive reaction to test will only be enrolled in the study. 7.Subject who does not have any previous history of adverse skin conditions and is not under any medication likely to interfere with the results. 8.The subject is in good general health as determined by the Investigator based on medical history. 9.Subject willing to maintain the test patches in designated positions for 24 Hours. 10.The subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits. 11.Subject must be able to understand and provide written informed consent to participate in the study. 12.The subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given.

Exclusion criteria

Exclusion criteria: 1. Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g., tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e., back that can interfere with the reading. 2. Medication which may affect skin response and/or past medical history. 3. Subject having history of diabetes 4. Subjects have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months. 5. Subject suffering from any active clinically significant skin diseases which may contraindicate. 6. Subject having history of any skin diseases including eczema, atopic dermatitis, or active cancer. 7. Participation in any patch test for irritation or sensitization within the last four weeks. 8. Subject having history of asthma or COPD (Chronic obstructive pulmonary disease). 9. Subject with Self-Reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous. 10. An individual who has a medical condition or is taking or has taken a medication which, in the Investigator’s judgment, makes the subject ineligible or places the subject at undue risk. 11. Subject with known allergy or sensitization to medical adhesives, bandages. 12. Participation in other patch study simultaneously. 13. Use of any: a. Prescribed or over the counter (OTC) anti-inflammatory drug within five (5) days prior to application. b. Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. c. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and/or eye drops are permitted) d. Topical drugs used at application site.

Design outcomes

Primary

MeasureTime frame
1. Number of subjects that showed No significant irritation. 2. Score of less than or equal to 2 on the Draize scale.Timepoint: Day 1, Day 2, Day 3, Day 9

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactMeena Dalal

Dabur India Limited

sasibhushan.vedula@dabur.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026